Biotech Values

[poorgradstudent]

The problem for the combination at this point is whether there is a time threshold for when the PML risk rises substantially.

In other words, if people had a higher risk of full blown PML after two years of combination use, would I as a chronic disease patient risk 6 months combo use? 1 year?

We'll see how this shakes out, but it appears to me that combo use is going to have a very difficult time even if these two events are deemed unrelated to therapy. For the time being, it appears that patients depending on monotherapy use are the innocent bystanders.